HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

TKNO

Alpha Teknova, Inc. (NASDAQ)

Healthcare — Drug Manufacturers - Specialty & Generic

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

None 3 analysts
$6.03
+$0.14 (+2.47%)
Target: $9.00 (49.4%)
Sign in to add TKNO to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$323.02M
P/E Ratio (TTM)-
Forward P/E-24.59
EPS (TTM)$-0.31
Dividend Yield-
Profit Margin-41.07%
Revenue Growth13.10%
ROE-23.92%
Debt/Equity42.86
Recommendation None
Analyst Target$9.00
Analysts3
Indexes NASDAQ

Technical Indicators

RSI (14)76.9
Beta0.63
SMA 20-
SMA 40-
52-Week High$6.68
52-Week Low$1.91
50-Day Avg$4.28
200-Day Avg$3.99
Avg Volume165.7K
Volume1.2K

Performance Analysis

NEUTRAL

TKNO presents a mixed picture with both positive and negative indicators.

+ Showing strength at 86% of its 52-week range.
- RSI at 76.9 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 13.1% year-over-year.
- Operating at a loss with -41.1% margin.
~ Wall Street consensus is "none" from 3 analysts.
+ Average analyst target of $9.00 implies 49.4% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:34 UTC

Back to Screener Export Report